US FDA approves Crinetics' oral pill for rare hormone disorder
25/09/2025 22:30
Sept 25 (Reuters) - The U.S. Food and Drug Administration approved Crinetics Pharmaceuticals' CRNX.O drug to treat a rare hormonal disorder on Thursday, making it the first once-daily oral pill available for patients in the country. The drug, chemically known as paltusotine and to be sold under the brand name Palsonify, was approved to treat acromegaly, a rare condition in which the pituitary gland in the brain produces excess growth hormone, causing the bones, organs and other tissues to grow bigger. This is caused due to a tumor on the pituitary gland. According to the U.S. National Institutes of Health, scientists estimate about 3 to 14 of every 100,000 people have been diagnosed as having acromegaly. (Reporting by Bageshri Banerjee, Sneha S K and Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber and Krishna Chandra Eluri) ((bageshri.banerjee@thomsonreuters.com;))